{
    "Trade/Device Name(s)": [
        "i-STAT CG8+ cartridge with the i-STAT 1 System"
    ],
    "Submitter Information": "Abbott Point of Care Inc.",
    "510(k) Number": "K223710",
    "Predicate Device Reference 510(k) Number(s)": [
        "K210958",
        "K183678"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CGA",
        "JJE"
    ],
    "Summary Letter Date": "June 28, 2023",
    "Summary Letter Received Date": "June 28, 2023",
    "Submission Date": "June 28, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Arterial whole blood",
        "Venous whole blood",
        "Capillary whole blood",
        "Plasma (by system description)"
    ],
    "Specimen Container(s)": [
        "Without anticoagulant",
        "Balanced heparin anticoagulant",
        "Lithium heparin anticoagulant",
        "Balanced heparin capillary tubes"
    ],
    "Instrument(s)/Platform(s)": [
        "i-STAT 1 analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Glucose oxidase-based amperometric peroxide detection"
    ],
    "Methodologies": [
        "Amperometric enzymatic detection"
    ],
    "Submission Type(s)": [
        "Cartridge",
        "Analyzer",
        "System",
        "Reagent",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for i-STAT CG8+ cartridge used with the i-STAT 1 System for point-of-care glucose measurement in whole blood.",
    "Indications for Use Summary": "Intended for in vitro quantification of glucose in arterial, venous, or capillary whole blood in point of care or clinical laboratory settings to aid in diagnosis, monitoring, and treatment of carbohydrate metabolism disorders.",
    "fda_folder": "Clinical Chemistry"
}